For Physicians



To evaluate a survival benefit for custirsen in combination with second-line cabazitaxel treatment in approximately 630 men with metastatic CRPC

Trial Design: 

Randomized, open-label, two-arm trial of custirsen in ~630 metastatic CRPC patients who have documented disease progression after prior first-line docetaxel treatment.

Arm A: 
Custirsen + Cabazitaxel + Prednisone
Arm B: 
Cabazitaxel + Prednisone
Primary Endpoint: 
Overall survival
Estimated Accrual Completion: 
December 2015

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue